---
title: "Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293525303.md"
description: "LifeSci Capital analyst Charles Zhu maintained a Buy rating on Revolution Medicines (RVMD) with an unchanged $263 price target, citing regulatory momentum for daraxonrasib in pancreatic cancer following FDA NDA acceptance. The thesis highlights robust Phase 3 data, potential Q3 launch, and commercial upside from converting existing patients. J.P. Morgan also maintained a Buy rating with a $205 target."
datetime: "2026-07-22T21:35:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293525303.md)
  - [en](https://longbridge.com/en/news/293525303.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293525303.md)
---

# Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Revolution Medicines, retaining the price target of $263.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Charles Zhu has given his Buy rating due to a combination of factors, foremost among them the regulatory momentum behind daraxonrasib in pancreatic cancer. The FDA’s acceptance of the NDA for previously treated metastatic PDAC, backed by robust Phase 3 RASolute 302 data, positions the drug as a potential new standard of care, with the EMA also moving quickly on review.

Zhu also sees near-term commercial upside, noting that a 3Q launch is increasingly plausible and could be accompanied by a meaningful revenue boost from converting existing EAP patients to commercial use. While some investors are focused on the speculative possibility of a line-agnostic, first-line accelerated approval, his thesis rests more on the high probability of approval in the post-1L setting and the broader RAS inhibitor pipeline, all supporting the unchanged $263 price target and a favorable risk-reward profile for RVMD.

In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $205.00 price target.

### Related Stocks

- [RVMD.US](https://longbridge.com/en/quote/RVMD.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Renaissance Technologies LLC Takes $603,000 Position in Revolution Medicines, Inc. $RVMD](https://longbridge.com/en/news/296076880.md)
- [RVMD: Paradigm-shifting clinical results and robust financials drive accelerated launches and pipeline progress](https://longbridge.com/en/news/295029385.md)
- [Apple has Biggest Streaming Hit Ever: How ‘Ted Lasso’ Could Help Company’s Undervalued Segment](https://longbridge.com/en/news/295951147.md)
- [BeOne Allies With US' Revolution Medicines to Assess Novel RAS-Targeted Cancer Drugs](https://longbridge.com/en/news/295505885.md)
- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)